Crohn's Disease Therapeutics Market

The Crohn's disease therapeutics market was valued at US$ 10.23 billion in 2024 and is anticipated to reach US$ 13.33 billion by 2031, with a projected CAGR of 4.1% from 2025 to 2031.

Market Insights and Analyst View:Crohn's disease is a chronic inflammatory disorder that mainly impacts the gastrointestinal tract, particularly the terminal ileum and the beginning of the colon. This condition is marked by inflammation of the digestive tract lining, resulting in symptoms such as abdominal discomfort, diarrhea, and malnutrition. The expansion of the Crohn's disease therapeutics market is largely due to the rising incidence of the disease in Western nations, especially in the US. Furthermore, strategic initiatives by companies to maintain competitiveness in the market are driving growth. A notable rise in the adoption of advanced medical devices is expected to introduce new trends in the Crohn's disease therapeutics market during the forecast period.

Growth Drivers and Challenges:Crohn's disease is classified as an irritable bowel syndrome, a chronic inflammatory bowel disorder without a definitive cure. The precise cause of this condition remains unclear, but it is primarily attributed to an inappropriate immune response in the bowel to various factors such as drugs, toxins, infections, and intestinal microbes, particularly in genetically predisposed individuals. According to the National Library of Medicine, Crohn's disease (CD) is more prevalent in developed Western countries, notably in North America, northern Europe, and New Zealand. The onset of the disease typically occurs in individuals aged 15 to 30 and 40 to 60 years, with a higher prevalence in urban settings. The incidence rate is particularly high among individuals of northern European descent and Jewish ancestry, at approximately 3.2 per 1,000. However, recent research indicates a significant rise in incidence in Asia, Africa, and Australasia, likely due to rapid industrialization in these regions. Consequently, the alarming prevalence of Crohn's disease in these areas is propelling the growth of the Crohn's disease therapeutics market.

As reported by the National Institute of Health, Crohn's disease imposes a considerable economic burden, with direct healthcare costs averaging around US$ 3,500 per patient annually in Europe. The disease affects roughly 322 individuals per 100,000, although prevalence rates can differ significantly between countries. More than half of Crohn's disease patients may remain undiagnosed or exhibit symptoms similar to other digestive disorders. The condition is more frequently observed in women, with a ratio of three women affected for every man.

Pharmaceutical companies focused on developing treatments for irritable bowel syndrome are actively implementing awareness initiatives aimed at effectively managing this syndrome by educating the public about symptoms, diagnosis, and treatment options. In 2018, Allergan PLC and Ironwood collaborated to launch an Interactive Digital Destination platform designed to empower individuals to educate themselves and take action against digestive disorders. Thus, the increasing prevalence of irritable bowel syndrome is a key driver of growth in the Crohn's disease therapeutics market.

Strategic Insights

Report Segmentation and Scope:The analysis of the Crohn's disease therapeutics market has been conducted by examining various segments, including drug type, distribution channel, and geography. By drug class, the market is categorized into anti-inflammatory drugs, immune system suppressors, antibiotics, biologics, anti-diarrheal medications, and pain relievers. The biologics segment held the largest market share in 2023, while the anti-inflammatory drugs segment is projected to achieve the highest CAGR from 2023 to 2031.

In terms of end users, the market is segmented into hospital pharmacies, clinical pharmacies, and online platforms. The hospital pharmacy segment represented the largest share of the Crohn's disease therapeutics market in 2023. Geographically, the report covers the Crohn's disease therapeutics market in North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, Japan, India, Australia, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, UAE, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Regional Analysis:North America is the leading contributor to the global growth of the Crohn's disease therapeutics market. The Asia Pacific region is expected to exhibit the highest CAGR during the period from 2023 to 2031. The market growth in North America is driven by the increasing prevalence of chronic diseases, advancements in technology and access to innovative medical products, a growing elderly population, and the presence of key market players engaged in both new and existing product development. In 2023, the US accounted for the largest share of the Crohn's disease therapeutics market in North America.

Crohns Disease Therapeutics Market Report Scope

Industry Developments and Future Opportunities:The forecast for the Crohn's disease therapeutics market is based on a combination of various secondary and primary research findings, including key company publications, association data, and databases. According to company press releases, significant developments by major players in the Crohn's disease therapeutics market include:

In 2023, the US Food and Drug Administration (FDA) approved Rinvoq (upadacitinib), the first oral pill for treating moderate-to-severe Crohn's disease, intended for adult patients who have not responded adequately to TNF-blocking drug candidates.

In 2022, the FDA granted approval for Skyrizi for the treatment of adults with moderate-to-severe active cases of Crohn's disease.

In 2021, AbbVie Inc. announced the start of a Phase 3 trial for risankizumab, a humanized monoclonal antibody targeting the interleukin-23 (IL-23) pathway, aimed at assessing its efficacy and safety in patients with moderate-to-severe Crohn's disease.

In 2021, Takeda Pharmaceutical Company Limited initiated a Phase 3 trial for the oral compound TAK-721, a selective antagonist of the chemokine receptor CXCR3, to evaluate its efficacy and safety in patients with moderate-to-severe Crohn's disease.

Competitive Landscape and Key Companies:Key players in the Crohn's disease therapeutics market include Abbvie, Inc.; Johnson and Johnson Private Limited; GlaxoSmithKline Plc; Merck and Co., Inc.; Novartis Ag; Celgene Corporation; Genentech; Pfizer Inc.; Nestle Health Science; and Boehringer Ingelheim GmbH. Additionally, several other companies have been analyzed to provide a comprehensive overview of the market and its ecosystem. These companies are focusing on geographic expansion and new product launches to meet the increasing demand from consumers globally and to broaden their product offerings with specialized portfolios. Their international presence enables them to cater to a large customer base, thereby facilitating market growth.